Matthew Ringel D MD

Matthew Ringel D MD
ProfessorCollege of
445D McCampbell Hall 1581 Dodd Drive Columbus Ohio 43210
Phone:614-292-3800Fax: (614) 247-1622
  • Molecular Biology and Cancer Genetics
  • Administrative

Research Description

Dr. Ringel's research interests include molecular mechanisms involved in thyroid cancer invasion and metastasis; with an active interest in new drug testing for thyroid cancer therapy.

Current Publications

  • Nagy R, Ringel MDGenetic Predisposition for Nonmedullary Thyroid Cancer.Horm Cancer in press 10/22/2014
  • McCarty SK, Saji M, Zhang X, Knippler CM, Kirschner L, Fernandez S, Ringel MDBRAF activates and physically interacts with PAK to regulate cell motility.Endocr Relat Cancer in press 9/16/2014
  • Peterson LA, Litzendorf M, Ringel MD, Vaccaro PSSDHB gene mutation in a carotid body paraganglioma: case report and review of the paraganglioma syndromes.Ann Vasc Surg 28 1321.e9-12 7/1/2014
  • Lakshmanan A, Doseff AI, Ringel MD, Saji M, Rousset B, Zhang X, Jhiang SMApigenin in combination with Akt inhibition significantly enhances thyrotropin-stimulated radioiodide accumulation in thyroid cells.Thyroid 24 878-87 5/1/2014
  • Lee AA, Zhang X, Kirschner JM, Parlow AF, Saji M, Jarjoura D, Ringel MD, La Perle KM, Kirschner LS, Pringle DR, Vasko VV, Yu L, Manchanda PKFollicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice.J Clin Endocrinol Metab 99 E804-12 5/1/2014
  • Phay JE, Ringel MDMetastatic mechanisms in follicular cell-derived thyroid cancer.Endocr Relat Cancer 20 R307-19 12/1/2013
  • Yusof AM, Kothandaraman S, Zhang X, Saji M, Ringel MD, Tweedle MF, Phay JEDevelopment of a calcium-sensing receptor molecular imaging agent.Surgery 154 1378-84; discussion 1384 12/1/2013
  • Liyanarachchi S, Wojcicka A, Li W, Czetwertynska M, Stachlewska E, Nagy R, Hoag K, Wen B, Ploski R, Ringel MD, Kozłowicz-Gudzinska I, Gierlikowski W, Jazdzewski K, He H, de la Chapelle ACumulative risk impact of five genetic variants associated with papillary thyroid carcinoma.Thyroid 23 1532-40 12/1/2013
  • Ding H, Yusof AM, Kothandaraman S, Saji M, Wang C, Kumar K, Milum K, Carleton M, Pan X, Ringel MD, Tweedle MF, Phay JELocalization of CaSR antagonists in CaSR-expressing medullary thyroid cancer.J Clin Endocrinol Metab 98 E1722-9 11/1/2013
  • Ringel MD, Nabhan FApproach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies.J Clin Endocrinol Metab 98 3104-10 8/1/2013
  • Ma Y, McCarty SK, Kapuriya NP, Brendel VJ, Wang C, Zhang X, Jarjoura D, Saji M, Chen CS, Ringel MDDevelopment of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.J Clin Endocrinol Metab 98 E1314-22 8/1/2013
  • He H, Bronisz A, Liyanarachchi S, Nagy R, Li W, Huang Y, Akagi K, Saji M, Kula D, Wojcicka A, Sebastian N, Wen B, Puch Z, Kalemba M, Stachlewska E, Czetwertynska M, Dlugosinska J, Dymecka K, Ploski R, Krawczyk M, Morrison PJ, Ringel MD, Kloos RT, Jazdzewski K, Symer DE, Vieland VJ, Ostrowski M, Jarząb B, de la Chapelle ASRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility.J Clin Endocrinol Metab 98 E973-80 5/1/2013
  • Valle LA, Gorodeski Baskin RL, Porter K, Sipos JA, Khawaja R, Ringel MD, Kloos RTIn thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin.Thyroid 23 185-93 2/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: